In yesterday’s Wall Street session, Addex Therapeutics Ltd (NASDAQ:ADXN) shares traded at $0.93, up 1.09% from the previous session.
2 analysts cover Addex Therapeutics Ltd (NASDAQ:ADXN), according to research data. The consensus rating among analysts is ‘Underweight’. As we calculate the median target price by taking the range between a high of $1.05 and a low of $1.05, we find $1.05. Given the previous closing price of $0.92, this indicates a potential upside of 14.13 percent. ADXN stock price is now 27.70% away from the 50-day moving average and -46.79% away from the 200-day moving average. The market capitalization of the company currently stands at $18.42M.
Brokers who have rated the stock have averaged $1.05 as their price target over the next twelve months.
There have been several recent changes in the stakes of large investors in ADXN stock. A new stake in Addex Therapeutics Ltd shares was purchased by RENAISSANCE TECHNOLOGIES LLC during the first quarter worth $27,000. MILLENNIUM MANAGEMENT LLC invested $19,000 in shares of ADXN during the first quarter. In the first quarter, CITADEL ADVISORS LLC acquired a new stake in Addex Therapeutics Ltd valued at approximately $12,000. TWO SIGMA SECURITIES, LLC acquired a new stake in ADXN for approximately $11,000. In total, there are 6 active investors with 47.44% ownership of the company’s stock.
On Tuesday morning Addex Therapeutics Ltd (NASDAQ: ADXN) stock kicked off with the opening price of $0.9000. During the past 12 months, Addex Therapeutics Ltd has had a low of $0.55 and a high of $6.24. The fifty day moving average price for ADXN is $0.7283 and a two-hundred day moving average price translates $1.7481 for the stock.
The latest earnings results from Addex Therapeutics Ltd (NASDAQ: ADXN) was released for Jun, 2022. The company reported revenue of $0.42 million for the quarter, compared to $0.74 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -42.93 percent.
Addex Therapeutics Ltd(ADXN) Company Profile
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.